Treatment of renal AA-Amyloidosis associated with human immunodeficiency virus infection: a case report
Tóm tắt
We present a case of a young adult male who was treated successfully for renal AA-amyloidosis secondary to human immunodeficiency virus (HIV) infection using highly active anti-retroviral therapy (HAART). He presented with lobar pneumonia, acute kidney injury, nephrotic syndrome and newly diagnosed HIV infection and was initiated on HARRT and haemodialysis. Kidney biopsy was consistent with amyloid deposition of the AA-type. His clinical condition improved gradually and after 10 months of therapy, he regained sufficient excretory function to become dialysis independent. Two years later, he remained well, with a recovered CD4 count and a glomerular filtration rate of 63 mL/min/1.73 m2. Patients with renal AA-amyloidosis typically present with slowly progressive chronic kidney disease, often leading to end-stage kidney disease within months. To our knowledge, this is the first reported case of biopsy proven renal AA-amyloidosis in a newly diagnosed HIV positive patient to present with acute kidney injury leading to dialysis dependence over a period of 2 weeks, which was successfully treated using HAART.
Tài liệu tham khảo
Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71. https://doi.org/10.1056/NEJMoa070265.
Hassen M, Bates W, Moosa MR. Pattern of renal amyloidosis in South Africa. BMC Nephrol. 2019;20(1):406. https://doi.org/10.1186/s12882-019-1601-x.
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96. https://doi.org/10.1056/NEJMra023144.
Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585–603. https://doi.org/10.1016/j.rdc.2018.06.004(Epub 2018 Sep 7).
Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70(4):246–56.
Ozen S. Renal amyloidosis in familial Mediterranean fever. Kidney Int. 2004;65(3):1118–27. https://doi.org/10.1111/j.1523-1755.2004.00485.x.
Connolly JO, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN, Woolfson RG. Renal amyloidosis in intravenous drug users. QJM. 2006;99(11):737–42. https://doi.org/10.1093/qjmed/hcl092.
Ford E, Puronen C, Sereti I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Cur Opin HIV AIDS. 2009;4(3):206–14.
Chan-Tack K, Uche A, Greisman L, Redfield R, Ahuja N, Weinman E, et al. Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. Am J Med Sci. 2006;332(6):364–7.
Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013;254(1):78–101. https://doi.org/10.1111/imr.12079.
Coelho S, Fernandes A, Soares E, Valério P, Farinha A, Natário A, Sá J. Amyloidosis related to HIV—an unusual cause of nephrotic syndrome in HIV patients. Port J Nephrol Hypert. 2017;31(3):207–11.
Cozzi PJ, Abu-Jawdeh GM, Green RM, Green D. Amyloidosis in association with human immunodeficiency virus infection. Clin Infect Dis. 1992;14(1):189–91. https://doi.org/10.1093/clinids/14.1.189.
Kurz M, Burkhalter F, Dickenmann M, Hopfer H, Mayr M, Elzi L, Battegay M. Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART–a case series over 11 years in a cohort of 1,153 patients. Swiss Med Wkly. 2015;29(145):w14135. https://doi.org/10.4414/smw.2015.14135.
de Vallière S, Mary C, Joneberg JE, Rotman S, Bullani R, Greub G, Gillmore JD, Buffet PA, Tarr PE. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg. 2009;81(2):209–12 (Erratum in: Am J Trop Med Hyg. 2009 Oct;81(4):732).
Newey C, Odedra BJ, Standish RA, Furmali R, Edwards SG, Miller RF. Renal and gastrointestinal amyloidosis in an HIV-infected injection drug user. Int J STD AIDS. 2007;18(5):357–8. https://doi.org/10.1258/095646207780749691.
Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428–34. https://doi.org/10.1038/ki.2008.604(Epub 2008 Dec 3).
Nebuloni M, Barbiano di Belgiojoso G, Genderini A, Tosoni A, Riani LN, Heidempergher M, Zerbi P, Vago L. Glomerular lesions in HIV-positive patients: a 20-year biopsy experience from Northern Italy. Clin Nephrol. 2009;72(1):38–45. https://doi.org/10.5414/cnp72038.
Jung O, Haack HS, Buettner M, Betz C, Stephan C, Gruetzmacher P, Amann K, Bickel M. Renal AA-amyloidosis in intravenous drug users–a role for HIV-infection? BMC Nephrol. 2012;21(13):151. https://doi.org/10.1186/1471-2369-13-151.
Samikkannu T, Rao KVK, Arias AY, Kalaichezian A, Sagar V, Yoo C, et al. HIV infection and drugs of abuse: role of acute phase proteins. J Neuroinflammation. 2013;10(1):113.
Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford). 2003;42(2):362–6. https://doi.org/10.1093/rheumatology/keg101.
Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2003;22(6):371–5. https://doi.org/10.1007/s10067-003-0763-9(Epub 2003 Nov 7).
Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10–21 year follow up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol. 1993;20(12):2051–7.